Featured Story | | | Monday, August 21, 2017 Samsung Bioepis has begun its long-anticipated move into novel drug R&D. The offshoot of South Korean conglomerate Samsung is taking its first steps beyond the lower risk, lower reward world of biosimilars by teaming up with Takeda to co-develop drugs against diseases including pancreatitis. |
|
|
| This week's sponsor is FierceBiotech Drug Development Forum. | | | Save 15% on the FierceBiotech 2nd Drug Development Forum
Network with 300+ biotech leaders and 90+ executive-level speakers at the largest biotech conference for optimizing pipeline strategies, partnerships and deal making September 25-27 in Boston, MA. Sign up today & save 15% w/ code C942FIERCE. |
Top Stories Monday, August 21, 2017 AstraZeneca has expanded its mRNA activities through an agreement with Ethris. The Big Pharma is paying €25 million ($29 million) upfront to work with Ethris on respiratory diseases and secure the option to license the fruits of the collaboration. Monday, August 21, 2017 Blade Therapeutics is looking to sharpen its focus after hiring Bristol-Myers Squibb’s former fibrosis research lead as its new EVP of research. The biotech, which is working on antifibrotic (scarring) therapies, has appointed Maria E. Fuentes, Ph.D., to lead its antifibrotic programs in preclinical testing. Monday, August 21, 2017 Alkermes has started a rolling application to market its twice-failed antidepressant ALKS 5461, hoping that the sum of all its clinical evidence will be enough to convince the FDA of its value. Monday, August 21, 2017 Former Zealand Pharma chief David Horn Solomon, M.D., has taken up the challenge of guiding biotech Akari during an increasingly tumultuous period. Monday, August 21, 2017 Cancer patient David Mitchell is so concerned about the potentially high price of CAR-T treatments that he requested a meeting with Joe Jimenez, CEO of Novartis, as the company works to establish a price for its upcoming product in this new class. | This week's sponsor is FierceBiotech. | | | FierceBiotech Executive Summit- London
Join FierceBiotech for our third annual Executive Summit in London. We'll gather the experts together to discuss innovation around R&D in the UK and look ahead to what's in store for 2018 with leaders in the field discussing trends in the industry. |
Resources Sponsored by: Veeva Learn why 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. Presented By: MPI Research FierceBiotech interviews Dr. DeWit to discuss a common cause for drug development delays, and strategies to avoid these costly setbacks. Sponsored by: Veeva Learn why 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Sponsored by: Veeva Join this global webinar to learn a new approach for demonstrating medical affairs' impact with better metrics - beyond reach and frequency, enabling launch success and better engagement with strategic KOL insights, and increasing your organization's share of voice in the healthcare landscape. 2nd Strategic Partnerships for Drug Repurposing Oct 26-27 | Boston, MA FierceBiotech 2nd Drug Development Forum September 25-27, 2017 | Boston, MA 15th Annual Discovery on Target September 25-29, 2017 | Boston, MA FierceBiotech Executive Summit- London October 2, 2017 | London Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA |
